Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

Todd Neale

March 08, 2024

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Shelley Wood

May 09, 2023

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Shelley Wood

June 01, 2020

News Daily News

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

Shelley Wood

May 06, 2020

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

Todd Neale

November 01, 2018

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Side Effects of Statins Might Be Overstated: CTT Collaboration

January 2026 Dispatch for the CV Team

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Little Pre- and Postmarket Testing for Most Recalled CV Devices

FDA Grants MACE Reduction Indication for Semaglutide

FDA Grants Tirzepatide a New Indication for Obesity Management

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

FDA Approves Empagliflozin for Treatment of HFpEF

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

FDA Approves Dapagliflozin for CKD Patients

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content